This study is NOT currently recruiting participants.
Number
11-C-0123
Sponsoring Institute
National Cancer Institute (NCI)
Recruitment Detail
Type: No longer recruiting/follow-up only Gender: Male & Female Min Age: 18 Years Max Age: 66 Years
Referral Letter Required
No
Population Exclusion(s)
Children;Pregnant Women;Fetuses
Keywords
Young TIL; Metastatic Melanoma; Immunotherapy; Adoptive Cell Therapy
Recruitment Keyword(s)
Metastatic Melanoma; Skin Cancer
Condition(s)
Investigational Drug(s)
Young TIL
Investigational Device(s)
None
Intervention(s)
Drug: Aldesleukin Drug: Cyclophosphamide Drug: Fludarabine Biological/Vaccine: Young TIL Radiation: Total Body Irradiation (TBI)
Supporting Site
National Cancer Institute
- An experimental treatment for metastatic melanoma involves cell therapy, in which researchers take white blood cells (lymphocytes) from the tumor tissue, grow them in the laboratory in large numbers, and then use the cells to attack the tumor tissue. Before receiving the cells, chemotherapy is needed to temporarily suppress the immune system to improve the chances that the tumor-fighting cells will be able to survive in the body. In some studies of cell therapy, individuals who have received total body irradiation (TBI) in addition to the chemotherapy (in order to increase the length of time that they do not produce white blood cells) seem to have a slightly better response to the treatment, but it is not known if adding radiation to the cell therapy will cause a better response for all individuals. Researchers are interested in comparing cell therapy given with the usual chemotherapy to cell therapy given with the usual chemotherapy and TBI.
Objectives:
- To compare the effectiveness of cell therapy given with chemotherapy to cell therapy given with chemotherapy and total body irradiation in individuals with metastatic melanoma.
Eligibility:
- Individuals at least 18 years of age who have been diagnosed with metastatic melanoma.
Design:
- Participants will be screened with a physical examination, medical history, blood tests, and tumor imaging studies.
- Participants will be divided into two groups: cell therapy with chemotherapy alone (group 1) or cell therapy with chemotherapy plus TBI (group 2).
- All participants will provide a tumor sample from either surgery or a tumor biopsy for white blood cell collection.
- Participants will have leukapheresis to collect additional white blood cells for cell growth and future testing, and TBI group participants will also provide stem cells to help them recover after radiation. (TBI participants who cannot provide enough stem cells will be moved to the non-radiation treatment group.)
- Participants will have chemotherapy with cyclophosphamide (two treatments over 2 days) and fludarabine (five treatments over 5 days) starting 7 days before the cell therapy. Participants in the TBI group will also have TBI for the 3 days immediately before the cell therapy.
- All participants will receive the white blood cells, followed by high-dose aldesleukin every 8 hours for up to 5 days after the cell infusion to help keep the therapy cells alive and active. Participants will also have injections of filgrastim to stimulate blood cell production, and participants in the TBI group will also receive their stem cells.
- Participants will take an antibiotic for at least 6 months after treatment to prevent pneumonia, and will be asked to return for regular monitoring and followup visits for at least 5 years to evaluate the tumor s response to treatment.
--Back to Top--
INCLUSION CRITERIA: a. Measurable metastatic melanoma with at least one lesion that is resectable for TIL generation. The lesion must be of at least 1cm in diameter that can be surgically removed with minimal morbidity (defined as any operation for which expected hospitalization less than or equal to 7 days). b. Patients with 3 or less brain metastases are eligible. Note: If lesions are symptomatic or greater than or equal to 1 cm each, these lesions must have been treated and stable for 3 months for the patient to be eligible. c. Greater than or equal to 18 years of age and less than or equal to 66 years of age. d. Willing to practice birth control during treatment and for four months after receiving all protocol related therapy. e. Life expectancy of greater than three months f. Willing to sign a durable power of attorney. g. Able to understand and sign the Informed Consent Document h. Clinical performance status of ECOG 0 or 1. i. Hematology: -Absolute neutrophil count greater than 1000/mm(3) -Hemoglobin greater than 8.0 g/dl -Platelet count greater than 100,000/mm(3) j. Serology: -Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities.) -Seronegative for hepatitis B antigen, or hepatitis C antibody or antigen. k. Chemistry: -Serum ALT/AST less than three times the upper limit of normal. -Calculated creatinine clearance (eGFR) > 50 ml/min. -Total bilirubin less than or equal to 2 mg/dl, except in patients with Gilbert s Syndrome who must have a total bilirubin less than 3 mg/dl. l. More than four weeks must have elapsed since any prior systemic therapy at the time of randomization, and patients toxicities must have recovered to a grade 1 or less (except for alopecia or vitiligo). Patients must have stable or progressing disease after prior treatment. Note: Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less or as specified in the inclusion criteria. m. Six weeks must have elapsed since any prior anti-CTLA4 antibody therapy to allow antibody levels to decline. Note: Patients who have previously received ipilimumab or tremelimumab, anti- PD1 or anti-PD-L1 antibodies, and have documented GI toxicity must have a normal colonoscopy with normal colonic biopsies. EXCLUSION CRITERIA: a. Prior cell transfer therapy which included a non-myeloablative or myeloablative chemotherapy regimen. b. Women of child-bearing potential who are pregnant or breastfeeding because 10 of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. c. Systemic steroid therapy requirement. d. Active systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease. e. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease and AIDS). f. Opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities.) g. History of severe immediate hypersensitivity reaction to any of the agents used in this study. h. History of coronary revascularization or ischemic symptoms. i. Any patient known to have an LVEF less than or equal to 45%. j. In patients > 60 years old, documented LVEF of less than or equal to 45%. k. Documented FEV1 less than or equal to 60% predicted tested in patients with: -A prolonged history of cigarette smoking (20 pk/year of smoking within the past 2 years) -Symptoms of respiratory dysfunction l. Prior radiation therapy that, in the judgment of the radiation oncologist, precludes the administration of total body irradiation.
a. Measurable metastatic melanoma with at least one lesion that is resectable for TIL generation. The lesion must be of at least 1cm in diameter that can be surgically removed with minimal morbidity (defined as any operation for which expected hospitalization less than or equal to 7 days).
b. Patients with 3 or less brain metastases are eligible. Note: If lesions are symptomatic or greater than or equal to 1 cm each, these lesions must have been treated and stable for 3 months for the patient to be eligible.
c. Greater than or equal to 18 years of age and less than or equal to 66 years of age.
d. Willing to practice birth control during treatment and for four months after receiving all protocol related therapy.
e. Life expectancy of greater than three months
f. Willing to sign a durable power of attorney.
g. Able to understand and sign the Informed Consent Document
h. Clinical performance status of ECOG 0 or 1.
i. Hematology:
-Absolute neutrophil count greater than 1000/mm(3)
-Hemoglobin greater than 8.0 g/dl
-Platelet count greater than 100,000/mm(3)
j. Serology:
-Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities.)
-Seronegative for hepatitis B antigen, or hepatitis C antibody or antigen.
k. Chemistry:
-Serum ALT/AST less than three times the upper limit of normal.
-Calculated creatinine clearance (eGFR) > 50 ml/min.
-Total bilirubin less than or equal to 2 mg/dl, except in patients with
Gilbert s Syndrome who must have a total bilirubin less than 3 mg/dl.
l. More than four weeks must have elapsed since any prior systemic therapy at the time of randomization, and patients toxicities must have recovered to a grade 1 or less (except for alopecia or vitiligo). Patients must have stable or progressing disease after prior treatment.
Note: Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less or as specified in the inclusion criteria.
m. Six weeks must have elapsed since any prior anti-CTLA4 antibody therapy to allow antibody levels to decline.
Note: Patients who have previously received ipilimumab or tremelimumab, anti- PD1 or anti-PD-L1 antibodies, and have documented GI toxicity must have a normal colonoscopy with normal colonic biopsies.
EXCLUSION CRITERIA:
a. Prior cell transfer therapy which included a non-myeloablative or myeloablative chemotherapy regimen.
b. Women of child-bearing potential who are pregnant or breastfeeding because 10 of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.
c. Systemic steroid therapy requirement.
d. Active systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease.
e. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease and AIDS).
f. Opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities.)
g. History of severe immediate hypersensitivity reaction to any of the agents used in this study.
h. History of coronary revascularization or ischemic symptoms.
i. Any patient known to have an LVEF less than or equal to 45%.
j. In patients > 60 years old, documented LVEF of less than or equal to 45%.
k. Documented FEV1 less than or equal to 60% predicted tested in patients with:
-A prolonged history of cigarette smoking (20 pk/year of smoking within the past 2 years)
-Symptoms of respiratory dysfunction
l. Prior radiation therapy that, in the judgment of the radiation oncologist, precludes the administration of total body irradiation.
Principal Investigator
Referral Contact
For more information: